Wyeth's Prevnar sales booming

Nov. 4, 2004 at 1:10 PM

CHICAGO, Nov. 4 (UPI) -- Prevnar, the popular drug to prevent bacterial meningitis, is on course to make more than $1 billion this year, a report says.

Sales of Prevnar, made by the pharmaceutical giant Wyeth, soared 32 percent in the third quarter to $321 million, the Chicago Tribune said Thursday.

A recent financial statement indicated this came about in part because the company made upgrades and improvements to its manufacturing facilities over the last year.

Prevnar vaccine costs about $260 for the four-shot regimen given to infants and young children. A dose of flu vaccine, by contrast, fetches about $8.

Wyeth left the flu vaccine market entirely last year to focus resources on its more lucrative vaccine.

Related UPI Stories
Latest Headlines
Trending Stories
Nobel Prize in Chemistry awarded to DNA cell repair pioneers
Priest suspended after defending pedophilia in TV interview
U.S. asks how Islamic State militants got so many Toyotas
At least 17 dead in Carolinas, more flooding expected
NASA releases thousands of Apollo mission photos on Flickr